Overcoming therapeutic efficiency limitations against TRAIL-resistant tumors using re-sensitizing agent-loaded trimeric TRAIL-presenting nanocages
Open Access
- 1 March 2021
- journal article
- research article
- Published by Elsevier in Journal of Controlled Release
- Vol. 331, 7-18
Abstract
No abstract availableKeywords
Funding Information
- Korea Institute of Science and Technology
- National Research Foundation of Korea (2017R1A3B1023418, 2018R1A2B2007426)
- Ministry of Science and ICT, South Korea
This publication has 66 references indexed in Scilit:
- Inhibition of the mitochondrial pyrimidine biosynthesis enzyme dihydroorotate dehydrogenase by doxorubicin and brequinar sensitizes cancer cells to TRAIL-induced apoptosisOncogene, 2013
- Resistance to TRAIL in non-transformed cells is due to multiple redundant pathwaysCell Death & Disease, 2013
- TRAIL and doxorubicin combination enhances anti-glioblastoma effect based on passive tumor targeting of liposomesJournal of Controlled Release, 2011
- TRAIL-R4 Promotes Tumor Growth and Resistance to Apoptosis in Cervical Carcinoma HeLa Cells through AKTPLOS ONE, 2011
- Moving Metal Ions through Ferritin−Protein Nanocages from Three-Fold Pores to Catalytic SitesJournal of the American Chemical Society, 2010
- Phase 1b Study of Dulanermin (recombinant human Apo2L/TRAIL) in Combination With Paclitaxel, Carboplatin, and Bevacizumab in Patients With Advanced Non-Squamous Non–Small-Cell Lung CancerJournal of Clinical Oncology, 2010
- Doxorubicin CardiomyopathyCardiology, 2009
- Barriers to Effective TRAIL-Targeted Therapy of MalignancyJournal of Clinical Oncology, 2007
- Encapsulation of platinum anticancer drugs by apoferritinChemical Communications, 2007
- RETRACTED: Death-receptor activation halts clathrin-dependent endocytosisProceedings of the National Academy of Sciences of the United States of America, 2006